INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2017

NOTE 13. INTANGIBLE ASSETS

The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):


	September 30, 2017							December 31, 2016
	Remaining	Gross						Gross
	Useful Life	Carrying		Accumulated		Net Book		Carrying		Accumulated		Net Book
Amounts in thousands	(In years)	Amount		Amortization		Value		Amount		Amortization		Value
NUCYNTA product rights	8.3	$	1,019,978	$	(243,016)	$	776,962	$	1,019,978	$	(172,288)	$	847,690
CAMBIA product rights	6.3		51,360		(19,471)		31,889		51,360		(15,619)		35,741
Lazanda product rights	4.9		10,480		(4,852)		5,628		10,480		(3,979)		6,501
Zipsor product rights	4.6		27,250		(16,785)		10,465		27,250		(15,033)		12,217
		$	1,109,068	$	(284,124)	$	824,944	$	1,109,068	$	(206,919)	$	902,149

In September 2016, the United States District Court for the District of New Jersey ruled in favor of the Company in the Company's patent litigation against all three ANDA filers for the Company’s NUCYNTA franchise. Based upon the Court’s ruling, the Company expects market exclusivity until December 2025 for NUCYNTA ER, NUCYNTA and NUCYNTA oral solution (an unmarketed form of NUCYNTA). Based upon the Court’s ruling in 2016, the Company reviewed the useful life of the NUCYNTA product rights and extended that from the previous estimate of June 2025 to December 2025.

Based on finite-lived intangible assets recorded as of September 30, 2017, and assuming the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses were estimated as follows (in thousands):


	Estimated
	Amortization
Year Ending December 31,	Expense
2017 (remainder)	$	25,734
2018		102,939
2019		102,939
2020		102,939
2021		102,939
Thereafter		387,454
Total	$	824,944